



Pharmacy & Therapeutics Committee Meeting

Supplemental Slides

May 15, 2024
6:30PM – 8PM

Formulary Updates – Product Exclusions

Therapeutic Category	Drug	# Utilizers (6 mo.)	Formulary Preferred Alternatives
Antineoplastic Agents/ Kinase Inhibitors	IMBRUVICA*	28	BRUKINSA, CALQUENCE
Endocrine and Metabolic/ Phosphate Binder Agents	VELPHORO	47	calcium acetate, sevelamer carbonate, AURYXIA
Immunologic Agents/ Autoimmune Agents (Self-Administered)	HUMIRA	1600	Consult Physician

*Prior Use Exemption will be applied for the 28 current utilizers

Review of Autoimmune Indication-Based Management

- Autoimmune therapy class is dynamic
 - High-cost launch pricing
 - Year-over-year inflation
 - Supplemental indications
- Indication based management of this class was a strategy launched by CVS in 2017
- Manages utilization for specific drugs used to treat specific indications rather than managing formulary placement at a therapy class level
- Delivers value in the class and allows providers numerous preferred options for their patients
- Strategy was reviewed by the P&T Committee in November 2017 and implemented by the Plan on 1/1/2018

Autoimmune Class Preferred Products by Indication

Indication	Primary Preferred Product*	Secondary Preferred Product*
Plaque psoriasis	<ul style="list-style-type: none"> • adalimumab-adaz • Hyrimoz (adalimumab-adaz) • Otezla (apremilast) • Skyrizi (SC) (risankizumab-rzaa) • Sotyktu (deucravacitinib) • Stelara (SC) (ustekinumab) • Taltz (ixekizumab) • Tremfya (guselkumab) 	<ul style="list-style-type: none"> • Bimzelx (bimekizumab-bkzx) (after 2 primary preferred products) • Cimzia syringe (certolizumab pegol) (after 2 primary preferred products)
Ankylosing spondylitis	<ul style="list-style-type: none"> • adalimumab-adaz • Cosentyx (secukinumab) • Enbrel (etanercept) • Hyrimoz (adalimumab-adaz) • Rinvoq (upadacitinib) 	<ul style="list-style-type: none"> • Cimzia syringe (certolizumab pegol) (after 2 primary preferred products)
Psoriatic arthritis	<ul style="list-style-type: none"> • adalimumab-adaz • Cosentyx (secukinumab) • Enbrel (etanercept) • Hyrimoz (adalimumab-adaz) • Otezla (apremilast) • Rinvoq (upadacitinib) • Skyrizi (SC) (risankizumab-rzaa) • Stelara (SC) (ustekinumab) • Tremfya (guselkumab) 	<ul style="list-style-type: none"> • Cimzia syringe (certolizumab pegol) (after 2 primary preferred products)

Autoimmune Class Preferred Products by Indication

Indication	Primary Preferred Product*	Secondary Preferred Product*
Rheumatoid Arthritis	<ul style="list-style-type: none"> • adalimumab-adaz • Enbrel (etanercept) • Hyrimoz (adalimumab-adaz) • Kevzara (sarilumab) • Orencia (SC)/Orencia ClickJect (abatacept) • Rinvoq (upadacitinib) • Xeljanz/Xeljanz XR (tofacitinib) 	<ul style="list-style-type: none"> • Cimzia syringe (certolizumab pegol) (after 2 primary preferred products)
Non-Radiographic Axial Spondyloarthritis	<ul style="list-style-type: none"> • Cimzia syringe (certolizumab pegol) • Cosentyx (secukinumab) • Rinvoq (upadacitinib) 	None
Crohn's disease	<ul style="list-style-type: none"> • adalimumab-adaz • Hyrimoz (adalimumab-adaz) • Rinvoq (upadacitinib) • Skyrizi (SC) (risankizumab-rzaa) • Stelara (SC) (ustekinumab) 	<ul style="list-style-type: none"> • Cimzia syringe (certolizumab pegol) (after 2 primary preferred products)
Ulcerative colitis	<ul style="list-style-type: none"> • adalimumab-adaz • Hyrimoz (adalimumab-adaz) • Rinvoq (upadacitinib) • Stelara (SC) (ustekinumab) • Xeljanz/Xeljanz XR (tofacitinib) • Zeposia (ozanimod) 	None

We engage with prescribers across multiple touchpoints

to help enhance efficiency, lower costs and create better experiences

In the office



Engagement in advance of formulary changes creates transparency to cost, benefit design and medication history*

- Real-time benefits

In the pharmacy



EHR connectivity eases administrative burden and simplifies patient onboarding

- EHR connectivity

Behind the scenes



Driving cost savings for payors and their members using PBM capabilities*

- Prescriber messaging for formulary changes

Ongoing basis



Delivering ongoing clinical support and connects patients with financial assistance programs

- Prescriber messaging for lower-cost covered options
- Copay assistance



We anticipate that over 90% of patients will smoothly transition to a covered product by utilizing CVS Specialty pharmacy in conjunction with our EMR connectivity.

Prescriber outreach enabled with RxChange

For Providers



Messages sent to provider's EHR with a clear ask for a change and/or additional information – **reducing the need for additional faxes and phone calls**

Allows them to quickly and easily respond with an 'approve' or 'deny' message from their EHR resulting in **higher and faster response rates vs. faxes**

For Pharmacies



Response is systematically sent back to the requesting pharmacy

Client case study
Frictionless experience for members and prescribers

95%

adoption of preferred biosimilar over a 45-day period



Functionality available at Specialty, Mail Order, and CVS retail pharmacies
Source: CVS Specialty Operations, 2023

 **CVSHealth**

Illustrative example

RxChange

collaboration that lends itself to better patient outcomes

HUMIRA PEN (2/BOX) 40MG/0.4ML

Inject 40 mg (0.4ML) subcutaneous every other week

Qty: 2 pens

Refills: 6

Substitutions: Y

Date Written 7/31/2023

Last Filled: N/A

Note:

Prescriber's view

RxChange Request: Therapeutic Interchange Request :

From: CVS Specialty
Sent: August 1, 2023
To: Test Prescriber

Select Suggested Medication

HYRIMOZ PEN ~ 40MG/0.4ML

Original Medication

HUMIRA PEN (2/BOX) ~ 40MG/0.4ML

[View full Rx Details](#)

Notes From Pharmacy

Humira no longer covered on patients' insurance. Please switch to a covered alternative medication

Approve

Deny

Replace

Test Patient (F)

DOB: 2/14/1982 (41 years)
(123) 555-1234 (c)
1234 Sunshine Rd
Walnut Creek, CA 94565

Provider:

Test Prescriber
1234 Hummingbird Way
Walnut Creek, CA 94565
(925)555-4567 (p)
DEA: AP8642490

Pharmacy:

CVS Specialty
1127 Bryn Mawr Ave Ste A
Redlands, CA 92374

Example above does not represent actual EHR screens.
Formulary selections are plan specific and determined by payor selections.